Project Grant K22CA288932

Award Date 7/1/24
Completion Date 4/1/25
Dollars Obligated $389K
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This federal Project Grant award of $257,413 from the National Cancer Institute's (NCI) Cancer Research Manpower program (CFDA 93.398) will support the development and evaluation of an interactive visual aid (VIS) to facilitate patient-clinician communication and decision-making around stopping cancer treatment for patients with advanced cancer. The primary objectives are to: 1) assess patient-caregiver-clinician shared understanding following serious illness conversations, 2) develop and refine...
This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research), supports a research program project titled "Understanding Integration in Oncology Care and Association with Quality and Outcomes". The $2,282,687 grant, awarded on September 15, 2024, will fund a 5-year research effort led by Harvard Medical School with sub-awards to Dartmouth-Hitchcock Clinic, Stanford University, and other partners. The project aims to...
This Project Grant award of $637,596.00, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), will fund research to develop and test a video-based intervention strategy to reduce colorectal cancer information avoidance and increase screening uptake. The key products and services to be delivered under this award include: Conducting a randomized controlled trial (RCT) to evaluate the effectiveness of the video intervention in increasing colorectal cancer...
This federal Project Grant award of $621,732 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund a hybrid effectiveness-implementation trial to evaluate a proactive identification and digital mental health intervention approach to address unmet psychosocial needs of individuals living with likely incurable cancer. The key products and services to be delivered under this 5-year grant include: 1) comprehensively assessing the...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $708,091 to Emory University to develop and test the effectiveness of the Algorithm-Enabled Patients Activated in Cancer Care through Teams (A-PACT) intervention. The A-PACT intervention aims to improve goals of care communication and reduce unwanted care utilization for patients with cancer. It uses machine learning algorithms to automatically...
This $459,867 project grant, awarded by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) on September 1, 2024, aims to create applied informatics technologies for cancer surveillance research and survivorship care in patients treated with immune checkpoint inhibitors (ICIs). The key products/services are: Conducting a clinical trial to assess the feasibility and effectiveness of informatics-assisted detection of immune-related adverse events (IRAEs) from...
This $164,692 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The grant supports research conducted by the Regents of the University of California, San Francisco (UCSF) to develop a novel framework for accurately detecting interactions in combinatorial screens with complex, high-dimensional phenotypic profiles. The goal is to establish a robust null interaction model that can better quantify interactions...
The National Cancer Institute (NCI) awarded a $1,338,648 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Pittsburgh to conduct a hybrid type I cluster randomized effectiveness-implementation trial of the CARES intervention. CARES is an integrated electronic health record-based screening and stepped collaborative care intervention aimed at improving health-related quality of life for cancer patients experiencing depression, pain, and/or...
This federal Project Grant award for $138,742 from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) supports research to investigate alterations in cellular communication networks in pancreatic ductal adenocarcinoma (PDAC) in response to immunotherapy treatments. The primary objectives are to: 1) develop statistical methods to analyze single-cell RNA sequencing data to identify cellular interactions that differ between immunotherapy treatment groups in...
This $334,233 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will support a research project conducted by the University of South Carolina. The project aims to examine disparities in the use of novel cancer therapies, the effects of comorbidities on cancer outcomes, and multi-level contributors to survival disparities for lung and colon cancer patients, particularly among racial minorities and rural...

This federal Project Grant award for $388,800.00, issued by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, supports a multilevel intervention to address communication barriers about complementary and alternative therapies (CAM) for cancer patients. The key products/services to be delivered through this award include:

  1. Engaging providers and patients to develop a CAM Question Prompt List (CAM-QPL) using qualitative methods (Aim 1).
  2. Estimating the initial efficacy of the CAM-QPL implemented as a multilevel intervention, including a physician-facing workshop on effective CAM conversation strategies (Aim 2).
  3. Conducting a qualitative exploration of patient and provider experiences with the multilevel intervention and revising it accordingly (Aim 3).

The overarching goal is to facilitate open conversations between cancer patients and providers about CAM, empower patients to navigate cancer-related information/misinformation, and build trust to support adherence to evidence-based treatments. The award period is from July 1, 2024 to April 1, 2025.

Generated 6/17/25, 2:10 AM